Pricing Log in Create free account

Celyad SA (CYAD) vs IGC Pharma, Inc. (IGC)

Celyad SA and IGC Pharma, Inc. are both Biotechnology companies. IGC Pharma, Inc. is the larger, with a market value of $26.3M against $23.8M — 1.1× the size. Celyad SA has the higher net margin (0.00% vs −795.5%) and the higher return on invested capital (0.00% vs −91.5%). Across the 14 metrics below, Celyad SA leads on 9 and IGC Pharma, Inc. on 5.

Valuation

Metric CYAD IGC Biotechnology median
P/E n/m n/m 8.50
P/S n/m 22.78 9.71
P/B 11.18 4.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA — n/m 0.64
EV/Sales — 23.44 9.21
Earnings yield (708.87%) (36.00%) (33.15%)
Free cash flow yield (438.06%) (22.67%) (25.50%)

Profitability

Metric CYAD IGC Biotechnology median
Gross margin 0.00% 32.33% 65.16%
Operating margin — (912.44%) 0.00%
Net margin 0.00% (795.46%) 0.00%
Free cash flow margin 0.00% (516.53%) 0.00%
Return on equity 0.00% (143.46%) (56.36%)
Return on assets 0.00% (100.44%) (48.04%)
Return on invested capital 0.00% (91.53%) 0.00%

Growth

Metric CYAD IGC Biotechnology median
Revenue growth (TTM) — (13.38%) 6.02%
EPS growth (last fiscal year) 113.33% 57.85% 30.26%
Revenue growth, 5-year CAGR (63.51%) (20.77%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYAD IGC Biotechnology median
Debt to equity 0.00 0.18 0.00
Current ratio 0.94 0.39 4.72
Net debt to EBITDA (1.62) 0.04 0.96

Dividend

Metric CYAD IGC Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CYAD IGC Biotechnology median
Market cap 23.79m 26.27m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack